Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

358 ARTÍCULOS , VIENDO DEL 256 AL 270

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease

Delnomdedieu M, Duvvuri S, Li DJ, Atassi N, Lu M, Brashear HR, Liu E, Ness S, Kupiec JW.

Alzheimers Res Ther. 2016 Mar 1;8(1):12. doi: 10.1186/s13195-016-0177-y.

Tempol and perindopril protect against lipopolysaccharide-induced cognition impairment and amyloidogenesis by modulating brain-derived neurotropic factor, neuroinflammation and oxido-nitrosative stress

Ali MR, Abo-Youssef AM, Messiha BA, Khattab MM.

Naunyn Schmiedebergs Arch Pharmacol. 2016 Jun;389(6):637-56. doi: 10.1007/s00210-016-1234-6. Epub 2016 Mar 30.

Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody

Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, Basun H, Lannfelt L.

Alzheimers Res Ther. 2016 Apr 6;8(1):14. doi: 10.1186/s13195-016-0181-2.

[Development of Disease-modifying Therapy for Alzheimer's Disease]

Akiyama H.

Brain Nerve. 2016 Apr;68(4):463-72. doi: 10.11477/mf.1416200419.

Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab

Russu A, Samtani MN, Xu S, Adedokun OJ, Lu M, Ito K, Corrigan B, Raje S, Liu E, Brashear HR, Styren S, Hu C.

J Alzheimers Dis. 2016 May 3;53(2):535-46. doi: 10.3233/JAD-151065.

Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials

Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, Tuchman M, Gass A, Fiebach JB, Hill D, Lobello K, Li D, McRae T, Lucas P, Evans I, Booth K, Luscan G, Wyman BT, Hua L, Yang L, Brashear HR, Black RS; Bapineuzumab 3000 and 3001 Clinical Study Investigators.

Alzheimers Res Ther. 2016 May 12;8(1):18. doi: 10.1186/s13195-016-0189-7.

Alterations in Glucose Metabolism in Alzheimer's Disease

Calsolaro V, Edison P.

Recent Pat Endocr Metab Immune Drug Discov. 2016;10(1):31-39. doi: 10.2174/1872214810666160615102809.

The Need for Early Detection and Treatment in Alzheimer's Disease

EBioMedicine. 2016 Jul;9:1-2. doi: 10.1016/j.ebiom.2016.07.001. Epub 2016 Jul 5.

European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow

Meulenbroek O, O'Dwyer S, de Jong D, van Spijker G, Kennelly S, Cregg F, Olde Rikkert M, Abdullah L, Wallin A, Walsh C, Coen R, Kenny RA, Daly L, Segurado R, Borjesson-Hanson A, Crawford F, Mullan M, Lucca U, Banzi R, Pasquier F, Breuilh L, Riepe M, Kalman J, Molloy W, Tsolaki M, Howard R, Adams J, Gaynor S, Lawlor B.

BMJ Open. 2016 Jul 19;6(7):e011584. doi: 10.1136/bmjopen-2016-011584.

A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's Disease

Malpas CB, Vivash L, Genc S, Saling MM, Desmond P, Steward C, Hicks RJ, Callahan J, Brodtmann A, Collins S, Macfarlane S, Corcoran NM, Hovens CM, Velakoulis D, O'Brien TJ.

J Alzheimers Dis. 2016 Jul 22;54(1):223-32. doi: 10.3233/JAD-160544.

Stimulating the Activity of Amyloid-Beta Degrading Enzymes: A Novel Approach for the Therapeutic Manipulation of Amyloid-Beta Levels

Kuruppu S, Rajapakse NW, Spicer AJ, Parkington HC, Smith AI.

J Alzheimers Dis. 2016 Oct 4;54(3):891-895. doi: 10.3233/JAD-160492.

Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies

Pardridge WM.

Expert Opin Biol Ther. 2016 Dec;16(12):1455-1468. doi: 10.1080/14712598.2016.1230195. Epub 2016 Sep 7.

Inflammation, Antiinflammatory Agents, and Alzheimer's Disease: The Last 22 Years

McGeer PL, Rogers J, McGeer EG.

J Alzheimers Dis. 2016 Oct 4;54(3):853-857. doi: 10.3233/JAD-160488.

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease

Brody M, Liu E, Di J, Lu M, Margolin RA, Werth JL, Booth K, Shadman A, Brashear HR, Novak G.

J Alzheimers Dis. 2016 Oct 18;54(4):1509-1519. doi: 10.3233/JAD-160369.

Towards Personalized Intervention for Alzheimer's Disease

Peng X, Xing P, Li X, Qian Y, Song F, Bai Z, Han G, Lei H.

Genomics Proteomics Bioinformatics. 2016 Oct;14(5):289-297. doi: 10.1016/j.gpb.2016.01.006. Epub 2016 Sep 28.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias